Disturbances of coagulation and fibrinolytic pathways were studied in 53 young patients with cerebral ischemia. Upon admission 26 of 53 patients had abnormality in at least one of the antithrombin-III, protein C, protein S activities or in activated protein C (APC) ratios. Three months after the first examination the majority of the previously detected abnormalities returned to normal values and the most frequent alterations were decrease in protein S activity (3 patients) and APC resistance (3 patients). Conditions resulting in impaired fibrinolysis were frequently detected upon admission. Elevation of plasminogen activator inhibitor-1, lipoprotein (a), and alpha-2-antiplasmin was present in 23, 10, and 4 cases, respectively. It is concluded that abnormalities of coagulation as well as of the fibrinolytic systems are prevalent in the acute phase of cerebral ischemia, however, the results may be significantly influenced by the disease process or the acute phase effect.

Keywords:
Young patients, Cerebral ischemia, Thrombophilia
1.
Adams HP, Butler MJ, Biller J, Toffol GJ: Nonhemorrhagic cerebral infarction in young adults. Arch Neurol 1986;43:793–796.
2.
Bogousslavasky J, Regli F: Ischemic stroke in adults younger than 30 years of age: Cause and prognosis. Arch Neurol 1987;44:479–482.
3.
Lisovski F, Rousseaux P: Cerebral infarction in young people: A study of 148 patients with early cerebral angiography. J Neurol Neurosurg Psychiatry 1991;54:576–579.
4.
Walker FJ: Regulation of activated protein C by a new protein: A possible function for protein S. J Biol Chem 1980;255:5521–5524.
5.
Horellou MH, Conard J, Bertina RM, Samama M: Congenital protein C deficiency and thrombotic disease in nine French families. BMJ 1984;289:1285–1287.
6.
Engeser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM: Hereditary protein S deficiency: Clinical manifestations. Ann Intern Med 1987;106:677–682.
7.
Kohler J, Kasper J, Witt I, von Reutern GM: Ischemic stroke due to protein C deficiency. Stroke 1992;23:108–111.
8.
Demers C, Ginsburg JS, Hirsh J, Henderson P, Blajchman MA: Thrombosis in antithrombin-III-deficient person: Report of a large kindred and literature review. Ann Intern Med 1992;116:754–761.
9.
Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004–1008.
10.
Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden P, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.
11.
Poort SR, Rosendaal FR, Reitsima PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698–3703.
12.
Lottenberg R, Dolly FR, Kitchens CS: Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. Am J Hematol 1985;19:181–193.
13.
Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M: Abnormal plasminogen: A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978;61:1186–1195.
14.
Nilsson IM, Ljungner H, Tengborn L: Two different mechanisms in patients with venous thrombosis and defective thrombolysis: Low concentrations of plasminogen activator or increased concentration of plasminogen activator inhibitor. BMJ 1985;290:1453–1456.
15.
Ratnoff OD: The role of haemostatic mechanisms. Clin Haematol 1981;10:261–281.
16.
D’Angelo A, Landi G, D’Angelo SV, Orazio EN, Boccardi E, Candelise L, Mannucci PM: Protein C in acute stroke. Stroke 1988;19:579–583.
17.
Camerlingo M, Finazzi G, Casto L, Laffranchi C, Barbui T, Mamoli A: Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991;41:1371–1373.
18.
Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 1993;119:819–827.
19.
Barinagarrementeria F, Cantú-Brito C, De La Pena A, Izaguirre R: Prothrombotic states in young people with idiopathic stroke. Stroke 1994;25:287–290.
20.
Green D, Otoya J, Oriba H, Rovner R: Protein S deficiency in middle-aged women with stroke. Neurology 1992;42:1029–1033.
21.
Simioni P, De Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A: Ischemic stroke in young patients with activated protein C resistance: A report of three cases belonging to three different kindreds. Stroke 1995;26:885–890.
22.
Anzola GP, Magoni M, Ascari E, Maffi V: Early prognostic factors in ischemic stroke: The role of protein C and protein S. Stroke 1993;24:1496–1500.
23.
Carolei A, Marini C, Ferranti E, Frontoni M, Prencipe M, Fieschi C, and the National Research Council Study Group: A prospective study of cerebral ischemia in the young: Analysis of pathogenic determinants. Stroke 1993;24:362–367.
24.
Martinez HR, Rangel-Guerra RA, Marfil AJ: Ischemic stroke due to deficiency of coagulation inhibitors: Report of 10 young adults. Stroke 1993;24:19–25.
25.
Fisher M, Fernández JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH: Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke 1996;27:1163–1166.
26.
Nagayama M, Nagayama T, Ohnuki Y, Shinihara Y: Expanded spectrum of coagulopathy in the etiology of cerebral infarction in younger adults in Japan. Cerebrovasc Dis 1996;6:350–355.
27.
Nowak-Gottl U, Strater R, Dubbers A, Oleszuk-Raschke K, Vielhaber H: Ischaemic stroke in infancy and childhood: Role of the Arg506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis 1996;7:684–688.
28.
Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M: Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994;14:1741–1745.
29.
Nagayama T, Shinohara Y, Nagayama M, Tsuda M, Yamamura M: Congenitally abnormal plasminogen in juvenile ischemic cerebrovascular disease. Stroke 1993;24:2104–2107.
30.
De Lucia D, Renis V, Belli A, Conte M, Di Mauro C, Tortora V, d’Alessio D, Nina PP, Franco A, Schisano G, Papa ML: Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks. J Neurosurg Sci 1996;40:25–35.
31.
Odegard OR, Lie M, Abildgaard U: Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975;6:287–294.
32.
Martinoli J, Stocker K: Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 1986;43:253–264.
33.
Wolf M, Boyer-Neumann C, Leroy-Matheron C, Martinoli JL, Contant G, Amiral J, Meyer D, Larrieu MJ: Functional assay of protein S in 70 patients with congenital and acquired disorders. Blood Coagul Fibrinolysis 1991;2:705–712.
34.
Chmielewska J, Wiman B: Determination of tissue plasminogen activator and its ‘fast’ inhibitor in plasma. Clin Chem 1986;32:482–485.
35.
Naito K, Aoki N: Assay of alpha2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. Thromb Res 1978;12:1147–1156.
36.
Silverstein RM: The determination of human plasminogen using Nalpha-CBZ-L-lysin p-nitrophenyl ester as substrate. Anal Biochem 1975;65:500–506.
37.
Borque L, Maside C, Iglesias A: Automated turbidimetry of serum lipoprotein (a). Eur J Clin Chem Clin Biochem 1993;31:869–874.
38.
Hart RG, Kanter MC: Hematologic disorders and ischemic stroke: A selective review. Stroke 1990;21:1111–1121.
39.
Mayer SA, Sacco RL, Hurlet-Jensen A, Shi T, Mohr JP: Free protein S deficiency in acute ischemic stroke: A case control study. Stroke 1993;24:224–227.
40.
Halbmayer W-M, Haushofer A, Schon R, Fischer M: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke, or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994;5:51–57.
41.
Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich J: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912–917.
42.
Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L, Palomaki H, Kaste M: Arg506Gln factor V mutation (factor V Leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558–560.
43.
Nabavi DG, Junker R, Wolff E, Ludemann P, Doherty C, Evers S, Droste DW, Kessler C, Assmann G, Ringelstein EB: Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: A case control study on 225 patients. J Neurol 1998;245:653–658.
44.
Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF: Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430–1433.
45.
Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastel JJ, Reitsma PH: The 20210 G→A mutation in the 3′-untranslated region of prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999;104:50–54.
46.
Giordano P, De Lucia D, Coppola B, Iolascon A: Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: A case report. Acta Haematol 1999;102:101–103.
47.
Edelberg JM, Reilly CF, Pizzo SV: The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1: The effects of fibrinogen, heparin, vitronectin, and lipoprotein (a). J Biol Chem 1991;266:7488–7493.
48.
El Sayed MS: Effects of high and low intensity aerobic conditioning programs on blood fibrinolysis and lipid profile. Blood Coagul Fibrinolysis 1996;7:484–490.
49.
Cimminiello C, Vigorelli P, Piliego T, Soncini M, Toschi V, Arpaia G, Perolini S, Bonfardeci C: Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol. Biomed Pharmacother 1997;51:164–169.
50.
Zenker G, Költringer P, Bone G, Niederkorn K, Pfeiffer K, Jürgens G: Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942–945.
51.
Kappelmayer J, Bereczki D, Misz M, Oláh L, Fekete I, Csiba L, Blasko G: Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc Dis 1998;8:235–239.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.